Tuesday, June 15, 2021


GLMD Galmed Pharmaceuticals Ltd. gains 17% Jun 15, 2021

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of a once-daily, oral therapy for the treatment of liver diseases. It is developing Aramchol, which is in ARREST study, a Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive